Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced that it has received a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category. The award recognizes the company's use of augmented intelligence in its Nociscan solution, which aims to help physicians identify the location of chronic low back pain—a condition affecting approximately 266 million people worldwide.
This latest recognition follows Aclarion's selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain. Together, these awards underscore growing external validation of Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making.
“Receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind our technology,” said Brent Ness, CEO of Aclarion. “Chronic low back pain remains one of the most challenging and costly conditions in medicine. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated.”
Aclarion's flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc's biochemical profile is consistent with a painful or non-painful disc. Physicians use this information—alongside imaging, clinical evaluation, and their own expertise—to optimize treatment planning for patients with discogenic low back pain. The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain.
Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure. According to Aclarion, Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. When used alongside other diagnostic tools, clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
The chronic low back pain market represents a significant healthcare burden, and Aclarion's technology offers a novel approach to diagnosis. By leveraging biomarkers and proprietary augmented intelligence algorithms, the company aims to provide physicians with objective data to guide treatment decisions. The Pinnacle Award highlights the innovative application of AI in clinical decision support, while the HLTH award previously recognized Nociscan's potential to revolutionize discogenic pain evaluation.
For more information about Aclarion and its technology, visit the company's website and newsroom. The company's latest updates are also available via its official news source.
